Authorized phase II of clinical trials of Cuban vaccine candidate against the COVID-19

Authorized phase II of clinical trials of Cuban vaccine candidate against the COVID-19

The Regulatory Authority for Medicines, Equipment and Medical Devices of the Republic of Cuba (CECMED) approved the start of the Phase II clinical trial with SOBERANA 02, a Cuban vaccine candidate against the COVID-19.

According to a message posted on the social network Twitter by the Finlay Vaccine Institute (IFV), the approval of the second phase of the clinical trial on SOBERANA 02 comes after the preliminary positive results of the Phase I.

The IFV adds that with this decision the first vaccine candidate to advance a Phase II clinical trials in all of Latin America is Cuban.

The start of the Phase II of the clinical trials on the SOBERANA 02 vaccine candidate was approved, after the preliminary positive results obtained with Phase I. Once again, the first Latin American vaccine candidate to advance to Phase II is Cuban; tweeted the Cuban entity.

The general director of the IFV, Vicente Verez Bencomo, highlighted on the social network that the vaccine candidate SOBERANA 01 also shows good preliminary results and the start of a second phase of its clinical trials is predicted for the month of January.